Please login to the form below
Semma Therapeutics
This page shows the latest Semma Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This programme has its roots in the groundbreaking work that began in Dr Doug Melton’s lab, progressed at Semma Therapeutics, and has been
Latest news
-
Vertex reveals promising data from first CRISPR-treated patients
Vertex paid CRISPR Therapeutics $105m upfront in 2015, with up to $420m in milestone payments, to tap into its gene-editing expertise. ... The American pharma giant also acquired Semma Therapeutics in September, which is focused on the use of stem cells
-
Vertex eyes type 1 diabetes cure with biotech acquisition
Will acquire Semma Therapeutics for $950m. American pharma company Vertex will acquire Semma Therapeutics, a biotech focused on finding a cure for type 1 diabetes. ... Semma was founded to develop therapies for type 1 diabetes patients who depend on
-
Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer
Competitors in the stem cell therapy for type 1 diabetes field include Semma Therapeutics, a Boston, Mass-based biotech.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch December 2016
and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... Antibody sequence for use with Trieza's viral vector technology. Semma Therapeutics.
-
Pharma deals in March 2015
Fujifilm expects to achieve significant synergies. Checkpoint inhibitors are not being left behind with two deals this month, one by Blueprint Ventures and the other by Checkpoint Therapeutics but neither are ... This month Semma Therapeutics raised $44m
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- The state of pharma customer experience
- GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
